Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Immorna Closes Series A+ and A++ Rounds Near $100M for mRNA Development
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++...
Sanofi’s VaxigripTetra Approved for Pediatric Influenza Vaccination in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical...
Enhertu Approved in China for HER2-Positive Breast Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
Novartis’ Revolade Approved for Severe Aplastic Anemia in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National...
Kelun-Biotech Files for Hong Kong IPO with Goldman Sachs and CITIC Securities
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its high-end preparation subsidiary,...
Accutar Biotech Begins Phase I Trial for AC0176 in China
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...
BeiGene’s Tislelizumab Approved for Gastric Tumors in China
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor...
SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...
Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review
China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND)...
Jacobio Pharma Partners with WestChina-Frontier for Preclinical Safety Studies
China-based Jacobio Pharma (HKG: 1167) has announced a partnership agreement with compatriot firm WestChina-Frontier PharmaTech,...
Mabwell’s IL-11 Monoclonal Antibody 9MW3811 Approved for Australian Clinical Trial
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving clinical trial approval from...
AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval
UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at...
CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai...
Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services
Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed...
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...